Otsuka Pharmaceutical Co. Ltd filed a complaint in the U.S. District Court for the District of New Jersey against Indian drugmaker Cadila Healthcare Ltd. and its U.S. subsidiary, Zydus Pharmaceuticals. The complaint states that Cadila and Zydus’ collaboration on an abbreviated new drug application (ANDA) for the active ingredient in Abilify® infringes an Otsuka patent. Otsuka is seeking to enjoin Zydus and Cadila from marketing or selling a generic Abilify® until their patent expires. Otsuka is represented by Finnegan.
Award/Ranking
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Award/Ranking
The National Law Journal Names Finnegan the Top Intellectual Property Law Department in DC
June 24, 2013
Media Mention
Revival of Aesthetic Functionality Doctrine Imperils Non-Traditional Marks, Panelists Say
March 13, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.